The US Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will try to answer a wide range of questions surrounding Nektar Therapeutics's novel opioid NKTR-181 (oxycodegol), which hang over the unstated philosophical question of whether the US market needs another opioid.
The advisory committees will evaluate the opioid during a 14 January joint session, where Nektar will advocate for the proposed...